BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
Bristol Myers Squibb (BMS) has discontinued development of ORM-6151, a targeted degrader therapy acquired from Orum Therapeutics in 2023. According to Orum's regulatory filing, BMS reviewed Phase 1 data and decided to stop further development. The deal, worth $100 million upfront and up to $80 million in milestones, will not require Orum to return the initial payment. Orum still has $180 million in cash and plans to focus on its remaining pipeline and DAC platform.
How this was made
The 30-second read
Why it matters
The termination removes future milestone liabilities for BMS but signals a pipeline gap.
Market read
Primary biotech news affecting BMS's pipeline outlook.
What to watch
Orum retains cash and other DAC programs, which could still generate value.
Background
BMS had acquired the asset from Orum in 2023 for $100M upfront; the program failed to meet expectations in Phase 1.
Ticker impact
BMS discontinued the ORM-6151 targeted degrader program after Phase 1 data, ending milestone payments.
Potential modest decline as investors reassess pipeline value.
Program termination signals a setback; no immediate financial loss but reduced future upside.
Market effects
May dampen sentiment for targeted protein degradation space.
Limited to US biotech sector.
Low global impact beyond biotech investors.
Counterpoint
BMS may reallocate resources to more promising assets, offsetting the loss.
Key entities
- CompanyBristol Myers Squibb
US-listed pharmaceutical company (ticker BMY).
- CompanyOrum Therapeutics
Korean biotech firm, private, developer of the discontinued program.
